Breaking News

Almac Expands Asia Pacific Ops

By Kristin Brooks | March 11, 2014

Establishes centers in Singapore and Japan

Almac has expanded its clinical services and technologies capabilities with regional hubs in Singapore and Japan to provide leadership, as well as technical, project and operational resources in Asia. The company is also establishing a new secondary packaging facility in Singapore to supply management and support drug pooling strategies aimed at optimizing the supply chain, which will open by the end of the year.  
Almac’s local teams support studies of various sizes and complexity and services are augmented by a web-based interface to monitor trial execution globally, with multi-lingual technical and project teams, and an in-house 24/7 hotline connecting site staff to on-call clinicians and unblinding specialists. According to the company, by positioning operational resources within the same time zones where trials are executed, Almac is able to resolve issues in less than 24 hours to eliminate communication delays and improve patient care.

Alan Armstrong, chief executive officer of Almac, said, “With 15% of all clinical trials conducted in Asia, it’s imperative that we provide localized service and support to our clients. We’ve long managed clinical trials on a global basis, but there’s now sufficient critical mass that requires we establish dedicated resources in the region. I’m pleased that our international expertise and global capabilities are now even more accessible to sponsors in this critically-important part of the world, and look forward to opening our new packaging facility later this year.”

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research